 |
 Video: What is a Stock Split?
|
|
|
| Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell therapies. Co. has several allogeneic cell therapy programs in development: OpRegen®, a retinal pigment epithelium cell replacement therapy for the treatment of advanced dry age-related macular degeneration with geographic atrophy; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injuries; VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells; and other product candidates in preclinical development covering a range of therapeutic areas and target tissues or organs. Co. has rights to HyStem, a patented biomaterial that mimics naturally occurring extracellular matrix. According to our Lineage Cell Therapeutics stock split history records, Lineage Cell Therapeutics has had 0 splits. | |
|
Lineage Cell Therapeutics (LCTX) has 0 splits in our Lineage Cell Therapeutics stock split history database.
Looking at the Lineage Cell Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lineage Cell Therapeutics shares, starting with a $10,000 purchase of LCTX, presented on a split-history-adjusted basis factoring in the complete Lineage Cell Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/29/2014 |
|
| End date: |
04/25/2024 |
|
| Start price/share: |
$2.54 |
|
| End price/share: |
$1.11 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-56.30% |
|
| Average Annual Total Return: |
-7.95% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$4,368.54 |
|
| Years: |
10.00 |
|
|
|
|
|
